Cargando…
A Phase 1 Trial of Highly Conformal, Hypofractionated Postprostatectomy Radiation Therapy
PURPOSE: This phase 1 trial aimed to identify the maximally tolerated hypofractionated dose schedule for postoperative radiation therapy (PORT) after radical prostatectomy. Secondary objectives included biochemical control and quality of life (QoL) measures. METHODS AND MATERIALS: Patients were trea...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677208/ https://www.ncbi.nlm.nih.gov/pubmed/36420197 http://dx.doi.org/10.1016/j.adro.2022.101024 |
_version_ | 1784833761880309760 |
---|---|
author | Patel, Krishnan R. Rowe, Lindsay S. Schott, Erica Cooley-Zgela, Theresa Ning, Holly Turkbey, Baris Choyke, Peter Lindenberg, Liza Mena, Esther Pinto, Peter A. Zhang, Qihu Shih, Joanna Salerno, Kilian E. Citrin, Deborah E. |
author_facet | Patel, Krishnan R. Rowe, Lindsay S. Schott, Erica Cooley-Zgela, Theresa Ning, Holly Turkbey, Baris Choyke, Peter Lindenberg, Liza Mena, Esther Pinto, Peter A. Zhang, Qihu Shih, Joanna Salerno, Kilian E. Citrin, Deborah E. |
author_sort | Patel, Krishnan R. |
collection | PubMed |
description | PURPOSE: This phase 1 trial aimed to identify the maximally tolerated hypofractionated dose schedule for postoperative radiation therapy (PORT) after radical prostatectomy. Secondary objectives included biochemical control and quality of life (QoL) measures. METHODS AND MATERIALS: Patients were treated on 1 of 3 dose levels (DLs): 56.4 Gy in 20 fractions (DL1), 51.2 Gy in 15 fractions (DL2), and 44.2 Gy in 10 fractions (DL3). Treatment was delivered to the prostate bed without pelvic nodal irradiation. Dose escalation followed a standard 3 + 3 design with an expansion for 6 additional patients at the maximally tolerated hypofractionated dose schedule. Acute dose-limiting toxicity (DLT) was defined as grade 3 toxicity lasting >4 days within 21 days of PORT completion; late DLT was defined as grade 4 gastrointestinal (GI) or genitourinary (GU) toxicity. RESULTS: Between January 2018 and August 2019, 15 patients underwent radiation treatment: 3 on DL1, 3 on DL2, and 9 on DL3. The median follow-up was 24 months. There were no DLTs, and the maximally tolerated hypofractionated dose schedule was identified as DL3. Two of the 15 patients (13.3%) experienced biochemical failure (prostate-specific antigen >0.1). Ten of 15 patients (67%) had grade 2+ acute toxicities, consisting of transient GI toxicities. Three patients experienced late grade 2+ GI toxicity, and 5 patients experienced late grade 2+ GU toxicity. Late grade 3 GU toxicity occurred in 2 patients. There were no grade 4+ acute or late toxicities. There were no significant differences in GI measures of QoL, however, there was an increase in GU symptoms and corresponding decrease in GU QoL between 12 and 24 months. CONCLUSIONS: The maximum tolerated hypofractionated dose schedule for hypofractionated PORT to the prostate bed was determined to be 44.2 Gy in 10 daily fractions. The most frequent clinically significant toxicities were late grade 2+ GU toxicities, which corresponded to a worsening of late GU QoL. |
format | Online Article Text |
id | pubmed-9677208 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-96772082022-11-22 A Phase 1 Trial of Highly Conformal, Hypofractionated Postprostatectomy Radiation Therapy Patel, Krishnan R. Rowe, Lindsay S. Schott, Erica Cooley-Zgela, Theresa Ning, Holly Turkbey, Baris Choyke, Peter Lindenberg, Liza Mena, Esther Pinto, Peter A. Zhang, Qihu Shih, Joanna Salerno, Kilian E. Citrin, Deborah E. Adv Radiat Oncol Scientific Article PURPOSE: This phase 1 trial aimed to identify the maximally tolerated hypofractionated dose schedule for postoperative radiation therapy (PORT) after radical prostatectomy. Secondary objectives included biochemical control and quality of life (QoL) measures. METHODS AND MATERIALS: Patients were treated on 1 of 3 dose levels (DLs): 56.4 Gy in 20 fractions (DL1), 51.2 Gy in 15 fractions (DL2), and 44.2 Gy in 10 fractions (DL3). Treatment was delivered to the prostate bed without pelvic nodal irradiation. Dose escalation followed a standard 3 + 3 design with an expansion for 6 additional patients at the maximally tolerated hypofractionated dose schedule. Acute dose-limiting toxicity (DLT) was defined as grade 3 toxicity lasting >4 days within 21 days of PORT completion; late DLT was defined as grade 4 gastrointestinal (GI) or genitourinary (GU) toxicity. RESULTS: Between January 2018 and August 2019, 15 patients underwent radiation treatment: 3 on DL1, 3 on DL2, and 9 on DL3. The median follow-up was 24 months. There were no DLTs, and the maximally tolerated hypofractionated dose schedule was identified as DL3. Two of the 15 patients (13.3%) experienced biochemical failure (prostate-specific antigen >0.1). Ten of 15 patients (67%) had grade 2+ acute toxicities, consisting of transient GI toxicities. Three patients experienced late grade 2+ GI toxicity, and 5 patients experienced late grade 2+ GU toxicity. Late grade 3 GU toxicity occurred in 2 patients. There were no grade 4+ acute or late toxicities. There were no significant differences in GI measures of QoL, however, there was an increase in GU symptoms and corresponding decrease in GU QoL between 12 and 24 months. CONCLUSIONS: The maximum tolerated hypofractionated dose schedule for hypofractionated PORT to the prostate bed was determined to be 44.2 Gy in 10 daily fractions. The most frequent clinically significant toxicities were late grade 2+ GU toxicities, which corresponded to a worsening of late GU QoL. Elsevier 2022-07-15 /pmc/articles/PMC9677208/ /pubmed/36420197 http://dx.doi.org/10.1016/j.adro.2022.101024 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Scientific Article Patel, Krishnan R. Rowe, Lindsay S. Schott, Erica Cooley-Zgela, Theresa Ning, Holly Turkbey, Baris Choyke, Peter Lindenberg, Liza Mena, Esther Pinto, Peter A. Zhang, Qihu Shih, Joanna Salerno, Kilian E. Citrin, Deborah E. A Phase 1 Trial of Highly Conformal, Hypofractionated Postprostatectomy Radiation Therapy |
title | A Phase 1 Trial of Highly Conformal, Hypofractionated Postprostatectomy Radiation Therapy |
title_full | A Phase 1 Trial of Highly Conformal, Hypofractionated Postprostatectomy Radiation Therapy |
title_fullStr | A Phase 1 Trial of Highly Conformal, Hypofractionated Postprostatectomy Radiation Therapy |
title_full_unstemmed | A Phase 1 Trial of Highly Conformal, Hypofractionated Postprostatectomy Radiation Therapy |
title_short | A Phase 1 Trial of Highly Conformal, Hypofractionated Postprostatectomy Radiation Therapy |
title_sort | phase 1 trial of highly conformal, hypofractionated postprostatectomy radiation therapy |
topic | Scientific Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677208/ https://www.ncbi.nlm.nih.gov/pubmed/36420197 http://dx.doi.org/10.1016/j.adro.2022.101024 |
work_keys_str_mv | AT patelkrishnanr aphase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy AT rowelindsays aphase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy AT schotterica aphase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy AT cooleyzgelatheresa aphase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy AT ningholly aphase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy AT turkbeybaris aphase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy AT choykepeter aphase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy AT lindenbergliza aphase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy AT menaesther aphase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy AT pintopetera aphase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy AT zhangqihu aphase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy AT shihjoanna aphase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy AT salernokiliane aphase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy AT citrindeborahe aphase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy AT patelkrishnanr phase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy AT rowelindsays phase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy AT schotterica phase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy AT cooleyzgelatheresa phase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy AT ningholly phase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy AT turkbeybaris phase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy AT choykepeter phase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy AT lindenbergliza phase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy AT menaesther phase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy AT pintopetera phase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy AT zhangqihu phase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy AT shihjoanna phase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy AT salernokiliane phase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy AT citrindeborahe phase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy |